Fibroblast growth factor 2 control of vascular tone

Nature Medicine

Volumn 4, Issue 2, 1998, Pages 201-207

  Zhou, Ming ^a   Sutliff, Roy L ^a   Paul, Richard J ^a   Lorenz, John N ^a   Hoying, James B ^a   Haudenschild, Christian C ^b   Yin, Moving ^a   Coffin, J Douglas ^c   Kong, Ling ^a   Kranias, Evangelia G ^a   Luo, Wusheng ^a   Boivin, Gregory P ^a   Duffy, John J ^a   Pawlowski, Sharon A ^a   Doetschman, Thomas ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HOLLAND LABORATORY   (United States)

^c MCLAUGHLIN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; HEMATOPOIESIS; HOMEOSTASIS; HYPOTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SMOOTH MUSCLE CONTRACTION; THROMBOCYTOSIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; CAROTID ARTERY INJURIES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEART; HEART RATE; HEMATOPOIESIS; MALE; MICE; MICE, KNOCKOUT; MUTATION; RECOMBINATION, GENETIC; VASOCONSTRICTION;

EID: 0031930918     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0298-201     Document Type: Article

References (44)

1. Kessler, D.S. & Melton, D.A. Vertebrate embryonic induction: Mesodermal and neural patterning. Science 266, 596-604 (1994).
2. Kimelman, D. & Kirschner, M. Synergistic induction of mesoderm by FGF and TGFbeta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell 51, 869-877 (1987).
3. Flamme, I. & Risau, W. Induction of vasculogenesis and hematopoiesis in vitro. Development 116, 435-439 (1992).
4. Slack, J.M. & Isaacs, H.V. The Einsteck-method: Position and structure of projections formed by implants of a ventral character. Dev. Biol. 161, 313-317 (1994).
5. Schneider, M.D., McLellan, W.R., Black, P.M. & Parker, T.G. Growth factors, growth factor response elements, and the cardiac phenotype. Basic Res. Cardiol. 87 (Suppl. 2), 33-48 (1992).
6. Parker, T.G., Packer, S.E. & Schneider, M.D. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J. Clin. Invest. 85, 507-514 (1990).
7. Folkman, J. & Klagsbrun, M. Vascular physiology: A family of angiogenic peptides. Nature 329, 671-672 (1987).
8. Doetschman, T., Shull, M., Kier, A. & Coffin, J.D. Embryonic stem cell model systems for vascular morphogenesis and cardiac disorders. Hypertension 22, 618-629 (1993).
9. Weiss, R.H. & Maduri, M. The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. J. Biol. Chem. 268, 5724-5727 (1993).
10. Ali, S., Davis, M.G., Becker, M.W. & Dorn, G.W.2. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J. Biol. Chem. 268, 17397-17403 (1993).
11. Itoh, H., Mukoyama, M., Pratt, R.E., Gibbons, G.H. & Dzau, V.J. Multiple autocrine. growth factors modulate vascular smooth muscle cell growth response to an- giotensin II. J. Clin. Invest. 91, 2268-2274 (1993).
12. Davis, M.G., et al. Intracrine and autocrine effects of basic fibroblast growth factor in vascular smooth muscle cells. J. Mol. Cell Cardiol. 29, 1061-1072 (1997).
13. Hebert, J.M., Basilico, C., Coldfarb, M., Haub, O. & Martin, G.R. Isolation of cDNAs encoding four mouse FGF family members and characterization of their expression patterns during embryogenesis. Dev. Biol. 138, 454-463 (1990).
14. Yanagisawa Miwa, A., et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257, 1401-1403 (1992).
15. Lindner, V. & Reidy, M.A. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 88, 3739-3743 (1991).
16. Tsuboi, R., Shi, CM., Rifkin, D.B. & Ogawa, H. A wound healing model using healing-impaired diabetic mice. J. Dermatol. 19, 673-675 (1992).
17. MacMillan, V., et al. Mice expressing a bovine basic fibroblast growth factor transgene in the brain show increased resistance to hypoxemic- ischemic cerebral damage. Stroke 24, 1735-1739 (1993).
18. Coffin, J.D., et al. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell 6, 1861-1873 (1995).
19. Thompson, S., Clarke, A.R., Row, A.M., Hooper, M.L. & Melton, D.W. Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells. Cell 56, 313-321 (1989).
20. Baird, A., Schubert, D., Ling, N. & Guillemin, R. Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 85, 2324-2328 (1988).
21. Arakawa, T., et al. The importance of Arg40 and 45 in the mitogenic activity and structural stability of basic fibroblast growth factor: Effects of acidic amino acid substitutions. J. Protein Chem. 14, 263-274 (1995).
22. Faham, S., Hileman, R.E., Fromm, J.R., Linhardt, R.J. & Rees, D.C. Heparin structure and interactions with basic fibroblast growth factor. Science 271, 1116-1120 (1996).
23. Sugi, Y., Sasse, J. & Lough, J. Inhibition of precardiac mesoderm cell proliferation by antisense oligodeoxynucleotide complementary to fibroblast growth factor-2 (FGF2). Dev. Biol. 157, 28-37 (1993).
24. Merle, P.L., Feige, J.J. & Verdetti, J. Basic fibroblast growth factor activates calcium channels in neonatal rat cardiomyocytes. J. Biol. Chem. 270, 17361-17367 (1995).
25. Lorenz, J.N. & Robbins, J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am. J. Physiol. 272, H1 137-H1146(1997).
26. Grupp, I.L., Subramaniam, A., Hewett, T.E., Robbins, J. & Grupp, G. Comparison of normal, hypodynamic, and hyperdynamic mouse hearts using isolated work-performing heart preparations. Am. J. Physiol. 265, H1401-H1410(1993).
27. Huang, P.L., et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239-242 (1995).
28. Cristiani, C., Volpi, D., Landonio, A. & Bertolero, F. Endothelin-1-selective binding sites are downregulated by transforming growth factor-beta and upregulated by basic fibroblast growth factor in a vascular smooth muscle-derived cell line. J. Cardiovasc. Pharmacol. 23, 988-994 (1994).
29. Sutter, M.C. & Ljung, B. Contractility, muscle mass and agonist sensitivity of isolated portal veins from normo- and hypertensive rats. Acta Physiol. Scand. 99, 484-495 (1977).
30. Schwartz, S.M. & Liaw, L. Growth control and morphogenesis in the development and pathology of arteries. J. Cardiovasc. Pharmacol. 21 (Suppl. 1), S31-S49 (1993).
31. Carmeliet, P., Moons, L., Ploplis, V., Plow, E. & Collen, D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99, 200-208 (1997).
32. Currier, J.W. & Faxon, D.P. Restenosis after percutaneous transluminal coronary angioplasty: Have we been aiming at the wrong target? J. Am. Coll. Cardiol. 25, 516-520 (1995).
33. Schwartz, S.M., Campbell, G.R. & Campbell, J.H. Replication of smooth muscle cells in vascular disease. Circ. Res. 58, 427-444 (1986).
34. Campbell, G.R. & Campbell, J.H. The phenotypes of smooth muscle expressed in human atheroma. Ann. N.Y. Acad. Sci. 598, 143-58, 143-158 (1990).
35. Aikawa, M., et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ. Res. 73, 1000-1012 (1993).
36. Aikawa, M., et al. Phenotypic modulation of smooth muscle cells during progression of human atherosclerosis as determined by altered expression of myosin heavy chain isoforms. Ann. N.Y. Acad. Sci. 748, 578-85, 578-585 (1995).
37. Allouche, M. Basic fibroblast growth factor and hematopoiesis. Leukemia 9, 937-942 (1995).
38. Muenke, M., et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nature Genet. 8, 269-274 (1994).
39. Rutland, P., et al. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nature Genet. 9, 173-176 (1995).
40. Jabs, E.W., et al. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nature Genet. 8, 275-279 (1994).
41. Rousseau, F., et al. Mutations in the gene encoding fibroblast growth factor receptor- 3 in achondroplasia. Nature 371, 252-254 (1994).
42. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390-397 (1996).
43. Burstein, S.A., Adamson, J.W., Thorning, D. & Harker, L.A. Characteristics of murine megakaryocytic colonies in vitro. Blood 54, 169-179 (1979).
44. Lalli, J., Harrer, J.M., Luo, W., Kranias, E.G. & Paul, R.J. Targeted ablation of the phospholamban gene is associated with a marked decrease in sensitivity in aortic smooth muscle. Circ. Res. 80, 506-513 (1997).